Pavan Choksi is a Partner at Arkitekt Ventures, a New York-based early-stage venture firm focused on advancing human. See sector focus and contact routes.
Pavan Choksi is a Partner at Arkitekt Ventures, a New York-based early-stage venture firm focused on advancing human health, and previously served as Co-Founder and Vice President of Business Development at Rx.Health before its 2023 acquisition by Commure[2][4]. His investment thesis targets early-stage companies (Seed and Series A) in frontier technologies applied to clinical medicine, including artificial intelligence, neurotechnology, and quantum computing[2][5]. Arkitekt Ventures typically invests check sizes between $3 million and $15 million, with Choksi participating in rounds such as the $10 million Series A for Olli Health[2][7]. Notable portfolio companies under his management include Paradromics, Parsley Health, Freenome, and Olli Health[2]. Choksi also serves as a board member of the NYU Innovation Venture Fund and sits on the Strategic Advisory Board for the Digital Medicine Society, reflecting his distinctive focus on bridging digital medicine with frontier tech[2][4]. He has not published public writing or a distinctive point of view beyond his firm’s mission to partner with founders building next-generation Health & Bio companies[5].
StartupFundraising tracks this investor record from SEC filings and announced rounds, updating focus, location and portfolio history as new data lands. Use it to gauge fit before an outreach, then widen the search to investors in New York.
Investors like Pavan Choksi · Full investor directory · Investor access · Company funding database